ICON Public (NASDAQ:ICLR) Price Target Cut to $290.00 by Analysts at Citigroup

ICON Public (NASDAQ:ICLR) had its target price cut by Citigroup from $300.00 to $290.00 in a report published on Monday,Benzinga reports. They currently have a buy rating on the medical research company’s stock.

Several other brokerages also recently commented on ICLR. The Goldman Sachs Group dropped their target price on ICON Public from $370.00 to $280.00 and set a “buy” rating on the stock in a report on Friday, October 25th. Barclays reduced their target price on shares of ICON Public from $330.00 to $275.00 and set an “overweight” rating on the stock in a research report on Friday, October 25th. Truist Financial reaffirmed a “buy” rating and set a $284.00 price target (down from $295.00) on shares of ICON Public in a report on Wednesday, December 18th. TD Cowen cut their price objective on shares of ICON Public from $369.00 to $285.00 and set a “buy” rating on the stock in a report on Friday, October 25th. Finally, Leerink Partnrs upgraded ICON Public to a “strong-buy” rating in a research note on Wednesday, September 18th. Four investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, ICON Public has a consensus rating of “Moderate Buy” and an average price target of $289.18.

ICON Public Stock Performance

NASDAQ ICLR opened at $215.51 on Monday. The business’s 50-day simple moving average is $211.79 and its 200-day simple moving average is $274.18. The firm has a market capitalization of $17.78 billion, a P/E ratio of 24.03, a P/E/G ratio of 1.54 and a beta of 1.20. ICON Public has a 1-year low of $183.38 and a 1-year high of $347.72. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.34 and a quick ratio of 1.34.

ICON Public (NASDAQ:ICLR) last released its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.72 by ($0.37). ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The business had revenue of $2.03 billion for the quarter, compared to analysts’ expectations of $2.13 billion. During the same quarter in the prior year, the firm earned $3.10 earnings per share. ICON Public’s quarterly revenue was down 1.2% compared to the same quarter last year. Equities analysts predict that ICON Public will post 13.42 EPS for the current year.

Institutional Trading of ICON Public

Several institutional investors have recently added to or reduced their stakes in ICLR. Ashton Thomas Private Wealth LLC acquired a new position in shares of ICON Public in the 2nd quarter valued at about $54,000. GAMMA Investing LLC boosted its stake in ICON Public by 64.0% in the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after acquiring an additional 169 shares during the period. EverSource Wealth Advisors LLC grew its holdings in shares of ICON Public by 39.2% during the second quarter. EverSource Wealth Advisors LLC now owns 394 shares of the medical research company’s stock valued at $129,000 after purchasing an additional 111 shares during the last quarter. Whittier Trust Co. of Nevada Inc. raised its position in shares of ICON Public by 23.1% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock worth $147,000 after purchasing an additional 96 shares during the period. Finally, First Horizon Advisors Inc. lifted its holdings in shares of ICON Public by 33.9% in the 3rd quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock worth $172,000 after purchasing an additional 151 shares during the last quarter. Institutional investors own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.